{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-098474","form_type":"8-K","ticker":"DSGN","cik":"0001807120","company_name":"Design Therapeutics, Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.250758+00:00","generated_at":"2026-05-15T18:06:34.098195+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Design Therapeutics reports Q4 2025 net loss of $16.0M; cash $219.8M funds operations into 2029","bullets":["Full-year 2025 net loss $69.8M; R&D expenses $59.1M, G&A $20.3M.","Cash, equivalents and securities $219.8M as of Dec 31, 2025; runway into 2029.","DT-216P2 (FA) RESTORE-FA trial ongoing; frataxin data expected H2 2026.","DT-168 (FECD) Phase 2 biomarker trial data anticipated H2 2026.","DT-818 (DM1) Phase 1 MAD trial dosing expected H1 2026; results in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-098474","json":"https://secwatch.observer/filing/0001193125-26-098474.json","markdown":"https://secwatch.observer/filing/0001193125-26-098474.md","text":"https://secwatch.observer/filing/0001193125-26-098474.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/0001193125-26-098474-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/dsgn-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:06:34.098195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}